Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 20/20 | 0.85 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1071205 | 1.00 | CALCRL (0.85) | CALCRLADRB2CYP3A4 | |
| SCHEMBL828503 | 1.00 | CALCRL (0.85) | CALCRLADRB2CYP3A4 | |
| SCHEMBL829336 | 0.94 | CALCRL (0.84) | CALCRLADRB2CYP3A4 | |
| SCHEMBL828697 | 0.94 | CALCRL (0.84) | CALCRLADRB2CYP3A4 | |
| SCHEMBL828517 | 0.92 | CALCRL (1.00) | CALCRLADRB2CYP3A4 | |
| SCHEMBL829244 | 0.92 | CALCRL (1.00) | CALCRLADRB2CYP3A4 | |
| SCHEMBL830435 | 0.91 | CALCRL (0.81) | CALCRLADRB2CYP3A4 | |
| SCHEMBL829215 | 0.91 | CALCRL (0.81) | CALCRLADRB2CYP3A4 | |
| SCHEMBL828333 | 0.91 | CALCRL (0.81) | CALCRLADRB2CYP3A4 | |
| SCHEMBL828596 | 0.91 | CALCRL (0.81) | CALCRLADRB2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271640-B1 | Piperidine derivatives as CGRP receptor antagonists | BRISTOL MYERS SQUIBB CO (US) | 2012-09-05 | — | — | EP | claimed |
| US-8044043-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | claimed |
| EP-2271640-A2 | PIPERIDINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2011-01-12 | — | — | EP | claimed |
| WO-2009126530-A2 | CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-15 | — | — | WO | claimed |
| US-20090258866-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-15 | — | — | US | claimed |
| EP-2271640-B1 | Piperidine derivatives as CGRP receptor antagonists | BRISTOL MYERS SQUIBB CO (US) | 2012-09-05 | — | — | EP | disclosed |
| US-8143403-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120010402-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2012-01-12 | — | — | US | disclosed |
| US-8044043-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2271640-A2 | PIPERIDINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009126530-A2 | CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-15 | — | — | WO | disclosed |
| US-20090258866-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010402-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | CALCRL 1/4885ADRB2 46/4885CYP3A4 3571/4885 |
| US-20090258866-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | CALCRL 1/4885ADRB2 46/4885CYP3A4 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.